- 1 Mpox diagnosis history, behavioural risk modification, and vaccination uptake in gay,
- 2 bisexual, and other men who have sex with men in the UK: findings from a large, online
- 3 community cross-sectional survey (RiiSH-Mpox) undertaken November/December 2022
- 4 Authors:
- 5 Ms Dana Ogaz^{1,3} (dana.ogaz@ukhsa.gov.uk)
- 6 Ms Qudsia Enayat¹ (qudsia.enayat@uksha.gov.uk)
- 7 Mr Jack RG Brown³ (jack.brown@ucl.ac.uk)
- 8 Ms Dawn Phillips¹ (dawn.phillips@uksa.gov.uk)
- 9 Ms Ruth Wilkie¹ (ruth.wilkie@ukhsa.gov.uk)
- 10 Ms Danielle Jayes¹ (danielle.jayes@ukhsa.gov.uk)
- 11 Mr David Reid^{2,3} (david.reid@ucl.ac.uk)
- 12 Prof Gwenda Hughes^{3,4,5} (gwenda.hughes@lshtm.ac.uk)
- Prof Catherine H Mercer^{2,3} (c.mercer@ucl.ac.uk)
- 14 Dr John Saunders^{1,2,3} (john.saunders@ukhsa.gov.uk)
- 15 Dr Hamish Mohammed^{1,2,3} (hamish.mohammed@ukhsa.gov.uk)
- 17 On behalf of the UKHSA Sexual Health Liaison Group:
- 18 Dr Katy Sinka¹ (katy.sinka@ukhsa.gov.uk)
- 19 Dr Helen Fifer¹ (helen.fifer@ukhsa.gov.uk)
- 20 Ms Hannah Charles¹ (hannah.charles@ukhsa.gov.uk)
- 21 Ms Helen Corkin¹ (helen.corkin@ukhsa.gov.uk)
- 22 Ms Norah O'Brien¹ (norah.obrien@ukhsa.gov.uk)
- 23 Dr Kate Folkard¹ (kate.folkard@ukhsa.gov.uk)
- 25 Affiliations:

16

- ¹ Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, United
- 27 Kingdom ² Institute for Global Health, University College London, London, United
- 28 Kingdom ³ The National Institute for Health and Care Research Health Protection Research
- 29 Unit in Blood Borne and Sexually Transmitted Infections at University College London in
- 30 partnership with the UK Health Security Agency, London, United Kingdom ⁴ Evaluation and
- 31 Translation Science Group, UK Health Security Agency, London, United Kingdom ⁵ UK
- 32 Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine,
- 133 NOTE This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Key words:

- 35 Mpox, GBMSM, vaccination, risk modification, behaviour, behaviour modification, vaccine
- 36 uptake

34

- 37 Corresponding author:
- 38 Ms Dana Ogaz (dana.ogaz@ukhsa.gov.uk)
- 39 UK Health Security Agency
- 40 61 Colindale Avenue
- 41 London, UK, NW9 5EQ
- 42 Contributions:
- 43 QE, DP, RW, DJ, DR, GH, CHM, JS, HM, KS, HF, HCh, HCo, NOB, and KF reviewed and
- 44 updated the survey instrument. Survey implementation, data collection and data management
- were carried out by QE, RW, and DR. DO, HM, and QE conceived analysis design with
- 46 review and contributions from DP, RW, DJ, DR, GH, CHM, JS, KS, KF. DO conducted
- analyses and, with JRGB, wrote the first manuscript draft. All authors contributed to
- 48 successive drafts and reviewed and approved the final manuscript.
- 49 Ethics statement:
- 50 Ethical approval of this study was provided by the UKHSA Research and Ethics Governance
- 51 Group (REGG; ref: R&D 524). Online informed consent was received from all participants
- and all methods were performed in accordance with guidelines and regulations set by the
- 53 UKHSA REGG.

- 54 Competing interests:
- 55 Authors have no competing interests to declare.
- 56 Data availability statement:
- 57 The data that support the findings of this study are available upon reasonable request from the
- 58 UK Health Security Agency (UKHSA). Requests can be directed to Dr Hamish Mohammed
- 59 (hamish.mohammed@ukhsa.gov.uk).

Funding:

61

- This study did not receive any funding and was conducted as part of the UKHSA public
- 63 health response to mpox.

64 Acknowledgements:

- The authors wish to thank all the participants who took part in this study. We acknowledge
- 66 members of the National Institute for Health and Care Research Health Protection Research
- 67 Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections (BBSTI) Steering
- 68 Committee: Professor Caroline Sabin (HPRU Director), Dr John Saunders (UK Health
- 69 Security Agency Lead), Professor Catherine Mercer, Dr Hamish Mohammed (previously
- 70 Professor Gwenda Hughes), Professor Greta Rait, Dr Ruth Simmons, Professor William
- 71 Rosenberg, Dr Tamyo Mbisa, Professor Rosalind Raine, Dr Sema Mandal, Dr Rosamund
- 72 Yu, Dr Samreen Ijaz, Dr Fabiana Lorencatto, Dr Rachel Hunter, Dr Kirsty Foster and Dr
- 73 Mamooma Tahir. The authors would also like to thank Takudzwa Mukiwa (Terrence Higgins
- 74 Trust) and Will Nutland (The Love Tank) for their review of the mpox module in the RiiSH-
- 75 Mpox survey used for this research.

Abstract (150/150):

Mpox cases, first identified as part of the multi-country outbreak in May 2022, rapidly fell in the UK from September 2022. Public health responses included community-coordinated messaging and a targeted mpox vaccination in eligible gay, bisexual, and other men who have sex with men (GBMSM). Using data from an online, community survey of GBMSM (November/December 2022), we examined self-reported mpox diagnoses, behavioural risk modification, and mpox vaccination offer and uptake (≥1 dose). Thirty-five participants (2.6%, 35/1,333) were ever mpox test positive; half (53%, 707/1,333) reported behaviour modification to avoid mpox. In GBMSM considered vaccine eligible, uptake was 69% (95% CI: 65%-72%, 601/875) or 92% (95% CI: 89%-94%, 601/655) in those eligible and offered. GBMSM self-identifying as bisexual, those with lower educational qualifications, and those unemployed were less likely to be vaccinated. Equitable mpox vaccine offer and provision is needed to minimise the risk of future outbreaks and mpox-related health inequalities.

Word Count: 3480/3500

Introduction

On 23 July 2022, the World Health Organization (WHO) declared the global mpox (formerly 'monkeypox') outbreak a Public Health Emergency of International Concern (1). To date, there have been over 85,000 confirmed mpox cases across 110 countries (2). Mpox virus can be transmitted through close, skin-to-skin contact with an infected individual (1). The 2022 outbreak was the first widespread international outbreak of mpox predominantly transmitted through sexually associated contact and disproportionately affecting gay, bisexual and other men who have sex with men (GBMSM) (1, 3-5).

Mpox was first detected in the UK in May 2022, but community transmission has been estimated to have started during the month prior (3, 5). Case numbers peaked in July 2022 and reached over 3,500 cases across the UK through year end. The UK Health Security Agency (UKHSA) enacted measures to curb rising infection rates, including raising public health awareness, advising a self-isolation period of 21 days for people with a diagnosis, comprehensive contact tracing of recent close sexual contacts, and a recommendation of a targeted vaccination campaign utilising Modified Vaccinia Ankara vaccine (6). UKHSA worked closely with community-based organisations to inform public health messaging to raise awareness and reduce the risk of mpox (7-9). An expert consensus panel, which included UKHSA, along with national and community sexual health organisations, estimated that 111,000 people would be eligible for mpox vaccination in the UK, including 103,000 GBMSM and 8,000 healthcare and outreach workers (10). The vaccination campaign, which began in June 2022 had vaccinated 70,837 people with a first dose, and 31,827 with a second through May 2023 (11). Case numbers in the UK rapidly subsided by the end of September 2022, with few reported cases in 2023 (12).

Vaccine delivery was initially targeted to London sexual health services (SHS), as residents of the capital comprised at least 69% of cases through September 2022 (10). National guidance recommended GBMSM at highest risk of mpox could be identified among those attending SHS, using similar markers of risk utilised in identifying those eligible for HIV pre-exposure prophylaxis (PrEP), irrespective of HIV status (6, 13). Vaccine eligibility criteria included a recent history of multiple recent sexual partners, group sex, attending sexon-premises venues or diagnosis of a bacterial sexually transmitted infection (STI). First doses were initially offered to eligible patients as a subcutaneous injection (6, 14), with

fractional dosing via intradermal administration also piloted and rolled out to maximise the coverage of the available vaccine supply (15). Observational, real-world studies have since reported 78%-86% vaccine effectiveness in preventing symptomatic mpox infection (16, 17).

In response to the UK mpox outbreak, the "Reducing inequalities in Sexual Health (RiiSH)-Mpox" survey was rapidly deployed from 24 November-19 December 2022 to assess the impact of the mpox outbreak on the health and well-being, sexual behaviour, and service-use among a community sample of GBMSM in the UK. We used these survey data to examine self-reported mpox diagnosis history, behavioural risk modification, and uptake of mpox vaccination among GBMSM in the UK.

Methods

Data collection and study design

The RiiSH-Mpox survey was adapted from an established methodology used to deliver a series of repeat, cross-sectional RiiSH surveys carried out initially in 2017 and during periods before and after COVID-19 related social restrictions in the UK (18, 19). The RiiSH-Mpox survey included all previous questions on service use and sexual risk behaviour but incorporated a novel module, developed with input from community stakeholders, relating to mpox diagnosis, vaccination uptake and behavioural risk modification in response to the mpox outbreak.

Setting and sampling

As in previous rounds of the RiiSH surveys, participants were recruited through adverts on social networking sites (Facebook, Instagram and Twitter) and Grindr, a geospatial networking (dating) application. Those included in analyses were aged ≥16 years, UK residents, self-identifying as men (cisgender/transgender), transgender women, or gender-diverse individuals assigned male at birth (AMAB), who reported having had sex with a man (cisgender/transgender) or gender-diverse individual AMAB in the last year. Online consent was obtained from all participants and no incentive was offered to participate.

Data analysis

Mpox testing and diagnosis history

We calculated the percentage and 95% confidence interval (CI) (Clopper-Pearson) of those ever reporting a mpox diagnosis history (i.e., positive mpox test) through survey

completion. As a sensitivity analysis, we calculated the percentage reporting a diagnosis history or self-perceived mpox in absence of a positive mpox test or self-reported testing history.

Using Pearson's chi-squared test, we assessed differences in sociodemographic, clinical, and behavioural characteristics (described below). Given the low number of participants with a diagnosis history, regression analyses were not conducted.

Mpox vaccination uptake

Mpox vaccination uptake was defined as the receipt of ≥1 mpox vaccine doses. Report of vaccine offer ("Have you been offered a vaccine for monkeypox?") was assessed in those not reporting uptake. We present the percentage and 95% CI of uptake among those offered a mpox vaccine and in all participants.

Mpox vaccination uptake in those mpox vaccination eligible

We examined uptake among those assumed to be eligible for mpox vaccination based on equivalent or proxy criteria outlined in national vaccination guidance (13). Using survey responses, vaccine eligibility was defined as the report of any of the following since August 2022: ≥ 10 physical male sex partners meeting any physical male sex partner(s) in a sex on premises venue, sex party, or cruising grounds (hereafter, public sex environment [PSE]); a positive STI test; or in the last year, report of: PrEP use (as a proxy for those at higher risk of mpox acquisition); or use of recreational drugs associated with chemsex (crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone). As a sensitivity analysis, we used a lower threshold of ≥ 5 physical male sex partners since August 2022, instead of > 10, to define eligibility.

Factors associated with mpox vaccination

We assessed factors associated with mpox vaccination using Pearson's chi-squared test and binary logistic regression. Sociodemographic variables with a significant association with vaccination in bivariate analysis were included in multivariable regression models sequentially assessing associations of key clinical and behavioural characteristics with mpox vaccination. Age-group and ethnicity were selected *a priori* for inclusion in multivariable modelling. A sensitivity analysis, examining sociodemographic factors associated with mpox vaccination in those considered mpox eligible, was also carried out.

Sociodemographic characteristics used in descriptive and regression analyses included: age-group, ethnicity, gender, sexual orientation, country of birth, UK nation of residence (England, Scotland, Wales, or Northern Ireland), education-level, employment, household composition (living alone or not), relationship status (single or in a relationship), and report of a comfortable financial situation (top two quartiles ["I am comfortable"/ "I am very comfortable"] from the question, "How would you best describe your current financial situation"). Clinical characteristics included: HIV status, uptake of ≥1 Hepatitis A vaccine dose(s), uptake of ≥ 1 Hepatitis B vaccine(s), and uptake of ≥ 1 human papillomavirus [HPV] vaccine doses (or the report of any in multivariable analyses). Behavioural risk modification as a result of the mpox outbreak was defined as the report of any of the following since May 2022: fewer sexual partners, reduced visits to sex on premises venues or PSE, and avoiding the following: any sex, condomless anal sex, skin-to-skin contact, visiting clubs or crowds. Sexual risk behaviour indicators, comprising mpox vaccination eligibility proxies, included: number and meeting place of male physical sex partners since August 2022, a positive STI test since August 2022, and in the last year, the report of PrEP use, or recreational drug use associated with chemsex. Lookback periods varied across sexual risk indicators to match those used in prior waves of the RiiSH survey or to focus on behaviours since the start of the mpox outbreak in May.

Due to small participant numbers in subgroups, we dichotomised ethnic (White, all other ethnic groups), gender (cisgender male, all other gender identity groups), and sexual orientation groups (gay/homosexual, bisexual [which includes those identifying as bisexual, straight, or "another way"]) for analyses.

Survey data were collected via the Snap Surveys platform and all data management and analyses were undertaken using Stata v15.0 (StataCorp, College Station, TX, USA). All p-values less than 5% were considered statistically significant.

Results

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

Of the 1,435 GBMSM that engaged with the RiiSH-Mpox survey in December 2022, 1,333 (93%) met gender identity and sexual history selection criteria to participate (Appendix I). Missing data were limited (<3% item non-response) as most survey questions were compulsory. Participants had a median age of 45 years (interquartile range [IQR]: 35-55, range: 16-78) (Table 1,4). Most self-identified as cisgender male (99%), gay/homosexual (89%), were of White ethnicity (92%), lived in England (86%), and were employed (81%).

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

Nearly half reported a comfortable financial situation (48%), two-thirds had degree-level qualifications (63%), and 15% of participants were living with HIV. Most participants were recruited from Facebook (58%), followed by Grindr (24%) and Twitter (15%). Of all participants, 53% (707/1,333) reported behavioural modification to avoid getting mpox, where the reduction in number of physical male sex partners (72% 510/707) was the most reported measure (Table 2). Mpox diagnosis history Among all participants, 2.6% (95% CI: 1.8%-3.6%; 35/1,333) reported a mpox diagnosis history. In our sensitivity analysis, an additional 17 participants without mpox test positivity (n=3) or test history (n=14) reported self-perceived mpox, bringing a total of 52 participants with either mpox test positivity or self-perceived mpox (3.9% [95% CI: 2.9%-5.1%]) (Appendix II, Appendix IV). Those with a mpox diagnosis history (n=35), compared to those without (n=1,298), were more likely to be older (91% vs 76% aged ≥35, p=0.031), born outside of the UK (37% vs 16%, p=0.001), report a comfortable financial situation (66% vs 48%, p=0.034), and living with HIV (37% vs 15%, p=<0.001). Higher levels of sexual health clinic engagement in the last year, recent STI test positivity, and sexual risk behaviours such as meeting partners at sex on premises venue, sex party, or PSE, were also reported in those with a mpox diagnosis history (Table 1). Both groups reported similar proportions of behaviour modification since May 2022 as a result of the mpox outbreak (49% vs 53%, p=0.592). These findings were similar to those found on the sensitivity analysis (Appendix IV). Mpox vaccination uptake Over half of participants were offered a mpox vaccination by a SHS (58%, 771/1,333); vaccination uptake was 52% (95% CI: 49%-55%; 692/1,333) among all participants, or 90% (95% CI: 87%-92%; 692/771) among those offered a vaccine (Table 3, Appendix III). Less than half of those reporting vaccination had received a second dose (41%, 288/692). Of GBMSM considered vaccine eligible (66%, 875/1,333), three-quarters (75%, 655/875) were offered a vaccine (Table 3, Appendix III). Vaccination uptake was 69% (95% CI: 65%-72%; 601/875) among all eligible participants, or 92% (95% CI: 89%-94%; 601/655) in those eligible and offered a vaccine. In those not vaccinated but offered a vaccine

(n=54), 48% (26/54) reported the decision not to get vaccinated (4.0% [26/655] of all eligible and offered), while a quarter of those eligible (25%, 220/875) were not offered a mpox vaccine. Second doses were reported by 41% (252/601) of eligible GBMSM vaccinated.

In sensitivity analyses using a lower threshold for multiple partners (≥ 5) to assume vaccine eligibility, there was a similar level of uptake (Appendix VI).

Factors associated with vaccination

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

Bivariate and multivariable associations with mpox vaccination uptake are presented in Table 4. We found evidence of bivariate association with mpox vaccination by age-group, sexual orientation, educational qualifications, employment, and current financial situation. In adjusted models, bisexual men (32% vs 54% in gay/homosexual men; aOR: 0.43, 95% CI: 0.29-0.62), those with education qualifications below degree-level (40% vs 59% in degreelevel or higher; aOR: 0.50, 95% CI: 0.39-0.63), and those not employed (37% vs 55% in those employed; aOR: 0.59, 95% CI: 0.43-0.80) were less likely to report mpox vaccination. Participants reporting a single relationship status were more likely to be vaccinated (54% vs 50% of those in a relationship; aOR: 1.27, 95% CI: 1.01-1.60). We found no evidence of independent association to age, though lowest levels of vaccination were seen in those aged 16-24 years (30% vs 58% in those aged 45-54 years; aOR: 0.47, 95% CI: 0.25-0.87); those aged 16-24 years comprised only 5% of those mpox vaccinated. Reporting a positive STI test since August 2022 (aOR: 4.09, 95% CI: 2.69-6.22), having a HAV, HBV, or HPV vaccination history (aOR: 5.27, 95% CI: 3.72-7.47), reporting higher numbers of physical sex partners since August 2022 (aOR: 7.73, 95% CI: 5.06-11.8, ≥10 partners vs 1 partner), and reporting PrEP use since December 2021 (aOR: 7.09, 95% CI: 5.49-9.15) were the greatest individual predictors of mpox vaccination following sociodemographic adjustment. Among mpox vaccinated GBMSM, 87% (601/692) met proxy mpox vaccination eligibility. Those who met mpox vaccination eligibility were 8-times more likely to have been vaccinated relative to those who did not (aOR: 8.38, 95% CI: 6.35-11.1).

In sensitivity analyses examining sociodemographic factors associated with mpox vaccination among those vaccine eligible, we found consistent findings to analyses among all participants, where mpox vaccine uptake was less likely in bisexual men (aOR: 0.49, 95% CI: 0.30-0.79 vs gay/homosexual men), those with lower educational qualifications (aOR: 0.46; 95% CI: 0.34-0.63), and those who were employed (aOR: 0.63; 95% CI: 0.42-0.95) (Appendix V).

Discussion

In this large, online community survey of GBMSM in the UK undertaken shortly after the 2022 mpox outbreak, one in two of all participants reported adopting a risk modification measure and seven in 10 eligible participants had been mpox vaccinated, with very high uptake in those that were offered a vaccine. Most participants who were vaccinated met proxy eligibility criteria, and among all participants, vaccine uptake was associated with higher levels of sexual risk, suggesting fidelity to targeted vaccination set out by national guidelines during rapid vaccine roll-out across the UK in June 2022. Demographic and behavioural characteristics of those mpox test positive broadly reflected those described in enhanced surveillance of confirmed cases undertaken by UKHSA (10). Over a third of those who tested positive for mpox were living with HIV, consistent with mpox case reporting (20, 21).

To our knowledge, this is the first study examining mpox vaccination and self-reported behavioural modification among a community sample of GBMSM in the UK. We found mpox vaccine uptake was similar to levels reported among all and eligible (51%, 66%, respectively) transgender people and GBMSM sexual health clinic attendees shortly following vaccination implementation in British Columbia (22). Changes to sexual behaviour have been reported among GBMSM in the UK during periods of COVID-19 restrictions, however, there has been limited evidence exploring behavioural modification in response to the 2022 mpox outbreak. While sexual mixing outside of households generally persisted through COVID-19 pandemic waves (19, 23), studies noted swift rebounds in sexual risk behaviour following easing of social restrictions (18). Our findings support other evidence of behavioural modification among GBMSM during the mpox outbreak, as UK surveillance data show a concurrent, but temporary decline in lymphogranuloma venereum (LGV) and *Shigella* species, infections that primarily circulate in the dense, interconnected sexual networks associated with mpox transmission (10, 24).

In our study, lower vaccine uptake was reported in those with lower educational qualifications and those without employment; these differences were also found in sensitivity analyses restricted to those considered vaccine eligible. These findings mirror COVID-19 vaccine uptake inequalities found in the previous RiiSH survey where, during the time of that survey (December 2021), UK COVID-19 vaccination was widely accessible (25). We found bisexual and straight-identifying participants also had a lower likelihood of reporting mpox

vaccination, consistent with findings in a smaller cross-sectional study exploring mpox vaccination uptake (22). The impact and epidemiology of mpox and associated morbidity in bisexual and heterosexual-identifying men who have sex with men (MSM) is unknown; a previous systematic review (26) reports lower sexual health service engagement despite high sexual risk in heterosexual-identifying MSM, suggesting a need for tailored vaccination promotion efforts for these groups in cases of mpox resurgence or endemicity, or with other sexually transmissible pathogens.

National guidance for targeting mpox vaccination recommended using markers of historical sexual risk shown to be associated with sexually transmitted infection (STI) and HIV incidence (27, 28). Most mpox vaccinated GBMSM met proxy eligibility criteria, however a third of those considered vaccine eligible did not report mpox vaccination, most of whom did not receive a vaccine offer. Findings could reflect SHS access barriers as only a third of those vaccine eligible and not offered a vaccine had visited a SHS since August 2022; in contrast, this may add to indications that some GBMSM do not regularly engage with SHS (29, 30). Vaccine provision and service-level constraints as a result of increased infection control measures needed for mpox management, as well as service reconfigurations, that included online triage, could have limited face-to-face offer and subsequent uptake (31, 32). To ensure anonymity of the respondents, the survey did not collect any data to indicate the region of residence of participants, where offer and uptake of vaccination may have been lower in regions of England that did not experience very large outbreaks or where local services did not provide vaccination. Individual-level barriers to vaccination, such as low perceived risk, may also have limited vaccine uptake among those eligible, especially once mpox incidence fell sharply across the UK after cases peaked in July.

Less than half of mpox-vaccinated participants reported already having received a second dose, despite only recent availability (September 2022) relative to survey completion, and is similar to the proportion reported nationally through May 2023 (11). Further work exploring low vaccine course completion is needed, especially as little data exist on the length of protection conferred following a single mpox vaccine dose and complete vaccination (33). Though rapid, first-dose vaccination provision has been recommended in the context of outbreak control following efficacy studies (16), since September 2022, UKHSA and the Joint Committee on Vaccination and Immunisation (JCVI) have recommended two dose offers in eligible groups (34), with the targeted mpox vaccination programme set to end in July 2023 (14).

Limitations

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

The RiiSH-Mpox survey is part of a series of repeat, cross-sectional surveys using consistent methodology, providing key behavioural insights that supplement routine national surveillance data for STIs and HIV. This study represents one of the few, timely examinations of mpox in a community sample of GBMSM, contextualising interpretation of the trends in the mpox outbreak in the UK. However, our study is subject to key limitations due to its cross-sectional design. We cannot determine the time of vaccination in relation to most reported sexual risk behaviours comprising eligibility. Moreover, given the report of behavioural risk modification resulting from the mpox outbreak, vaccine eligibility could be underestimated, though behaviour could have changed following vaccine uptake. While observational studies of GBMSM in the UK and other high-income countries have reported a high willingness to be vaccinated against mpox (35-37), uptake estimates may be subject to sampling and social desirability bias. RiiSH-Mpox participants may represent a more healthliterate sample, given higher educational attainment and employment relative to national probability survey estimates in GBMSM (38). Prior RiiSH cross-sectional samples have reported near universal uptake of complete COVID-19 vaccination (25). Though RiiSH-Mpox participants may not be representative of the wider GBMSM population in the UK, our study sample likely represents key groups targeted for mpox vaccination, in addition to vaccination for other sexually transmissible pathogens. Finally, small subgroup sizes across ethnicity and gender identity indicators limit assessment of inequalities in vaccine uptake.

Conclusion

While high mpox vaccine uptake in eligible GBMSM and adoption of risk modification measures likely led to the reduction of mpox incidence in July 2022, the degree of contribution of each in the UK is unknown. Prior to, and during the reactive vaccine programme, timely vaccine resource information distributed and amplified by community-based organisations for GBMSM and other groups at risk likely contributed to the sharp drop in mpox incidence by the end of 2022 (8, 39) .

In the UK, the use of key behavioural proxies guided mpox vaccination eligibility for GBMSM and facilitated vaccination implementation for those at risk of mpox. Any future targeted vaccination roll-out will need to consider rapid, yet equitable provision strategies, and must engage with the underserved via local outreach and community groups to maximise reach and vaccine uptake, and to minimise mpox-related stigma (40). Uptake barriers in

RiiSH-Mpox v_1.0

sexual minorities, and those with lower social and financial capital, groups already described to have unmet sexual health need (18), must be understood to minimise exacerbation of vaccine uptake inequalities. Moreover, effective vaccination offer and provision strategies for those utilising online sexual health services warrant exploration as sexual health reconfigurations, often led by online service expansion, continue. Optimising SHS and outreach-led mpox vaccine offer, as part of a package of preventative interventions for those who may have unmet need, should be considered to maximise the benefit of each sexual health contact.

To reduce the likelihood of any future mpox outbreaks given threats of resurgence, provision of first mpox vaccination doses and completion of the course of vaccination in those who have received their first dose must be urgently prioritised.

References

- 386 1. Ghebreyesus TA, World Health O. Why the monkeypox outbreak constitutes a public health
- emergency of international concern. BMJ. 2022 Aug 9;378:o1978.
- 2. Centers for Disease Control and Prevention. 2022 Global Map & Case Count. 2023 [cited
- 389 2023 24 March]; Available from: https://www.cdc.gov/poxvirus/mpox/response/2022/world-
- 390 map.html

- 391 3. The UK Health Security Agency (UKHSA). UK strategy for mpox control, 2022 to 2023.
- 392 2022 [cited 2023 24 March]; Available from: https://www.gov.uk/government/publications/mpox-
- 393 monkeypox-control-uk-strategy-2022-to-2023/uk-strategy-for-mpox-control-2022-to-2023
- 394 4. Inigo Martinez J, Gil Montalban E, Jimenez Bueno S, Martin Martinez F, Nieto Julia A,
- 395 Sanchez Diaz J, et al. Monkeypox outbreak predominantly affecting men who have sex with men,
- 396 Madrid, Spain, 26 April to 16 June 2022. Euro Surveill. 2022 Jul;27(27).
- 5. Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, et al. Community
- transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022
- 399 Jun;27(22):2200422.
- 400 6. The UK Health Security Agency (UKHSA). Mpox (monkeypox) outbreak vaccination
- strategy. 2022 [cited 2023 24 March]; Available from: https://www.gov.uk/guidance/monkeypox-
- 402 <u>outbreak-vaccination-strategy</u>
- The UK Health Security Agency (UKHSA). Mpox and sexual health: outreach and
- 404 engagement fund. 2022 [cited 2023 24 April]; Available from:
- 405 https://www.gov.uk/government/publications/mpox-and-sexual-health-outreach-and-engagement-
- 406 <u>fund</u>
- 407 8. Terrence Higgins Trust. Mpox (monkeypox) in the UK. 2023 [cited 2023 24 April];
- 408 Available from: https://www.tht.org.uk/hiv-and-sexual-health/sexual-health/mpox-monkeypox-uk
- 409 9. The Love Tank. 2023 [cited 2023 24 April]; Available from: http://thelovetank.info/
- 410 10. The UK Health Security Agency (UKHSA). Investigation into monkeypox outbreak in
- England: technical briefing 8. 2022 [cited 2023 24 March]; Available from:
- 412 https://www.gov.uk/government/publications/monkeypox-outbreak-technical-briefings/investigation-
- 413 into-monkeypox-outbreak-in-england-technical-briefing-8
- 414 11. NHS England. Vaccinations for mpox: MVA vaccinations 4 May 2023. 2023 [cited 2023 10]
- 415 May]; Available from: https://www.england.nhs.uk/statistics/statistical-work-areas/vaccinations-for-
- 416 mpox/
- 417 12. The UK Health Security Agency (UKHSA). Mpox (monkeypox) outbreak: epidemiological
- 418 overview, 4 May 2023. 2023 [cited 2023 10 May]; Available from:
- 419 https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-overview

- 420 13. The UK Health Security Agency (UKHSA). Smallpox and monkeypox: the green book,
- chapter 29. 2022 [cited 2023 15 February]; Available from:
- https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/110
- 423 <u>6454/Green-Book-chapter-29_Smallpox-and-monkeypox_26September2022.pdf</u>
- 424 14. The UK Health Security Agency (UKHSA). People still eligible for mpox vaccine urged to
- come forward. 2023 [cited 2023 24 March]; Available from:
- 426 https://www.gov.uk/government/news/people-still-eligible-for-mpox-vaccine-urged-to-come-forward
- 427 15. The UK Health Security Agency (UKHSA). Monkeypox vaccines to be piloted in smaller but
- 428 equally effective doses. 2022 [cited; Available from:
- 429 https://www.gov.uk/government/news/monkeypox-vaccines-to-be-piloted-in-smaller-but-equally-
- 430 effective-doses
- 431 16. Bertran M, Andrews N, Davison C, Dugbazah B, Boateng J, Lunt R, et al. Effectiveness of
- one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an
- observational study. Lancet Infect Dis. 2023 Mar 13.
- 434 17. Wolff Sagy Y, Zucker R, Hammerman A, Markovits H, Arieh NG, Abu Ahmad W, et al.
- Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med. 2023 Mar;29(3):748-
- 436 52.
- 437 18. Brown JR, Reid D, Howarth AR, Mohammed H, Saunders J, Pulford CV, et al. Changes in
- 438 STI and HIV testing and testing need among men who have sex with men during the UK's COVID-19
- pandemic response. Sex Transm Infect. 2022 Jul 21.
- 440 19. Howarth AR, Saunders J, Reid D, Kelly I, Wayal S, Weatherburn P, et al. 'Stay at home ...':
- exploring the impact of the COVID-19 public health response on sexual behaviour and health service
- 442 use among men who have sex with men: findings from a large online survey in the UK. Sex Transm
- 443 Infect. 2022 Aug;98(5):346-52.
- 20. Curran KG, Eberly K, Russell OO, Snyder RE, Phillips EK, Tang EC, et al. HIV and Sexually
- Transmitted Infections Among Persons with Monkeypox Eight US Jurisdictions, May 17-July 22,
- 446 2022. Mmwr-Morbidity and Mortality Weekly Report. 2022 Sep 9;71(36):1141-7.
- 447 21. Tarin-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suner C, Anton A, et al. Clinical
- 448 presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a
- prospective observational cohort study. Lancet. 2022 Aug 27;400(10353):661-9.
- 450 22. Gilbert M, Ablona A, Chang HJ, Grennan T, Irvine MA, Sarai Racey C, et al. Uptake of
- 451 Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men
- among sexually-transmitted infection clinic clients in Vancouver, British Columbia. Vaccine. 2023
- 453 Apr 6;41(15):2485-94.
- 454 23. Nadarzynski T, Nutland W, Samba P, Bayley J, Witzel TC. The Impact of First UK-Wide
- 455 Lockdown (March-June 2020) on Sexual Behaviors in Men and Gender Diverse People Who Have

- 456 Sex with Men During the COVID-19 Pandemic: A Cross-Sectional Survey. Arch Sex Behav. 2023
- 457 Feb;52(2):617-27.
- 458 24. Thorley K, Charles H, Greig DR, Prochazka M, Mason LCE, Baker KS, et al. Emergence of
- extensively drug-resistant and multidrug-resistant Shigella flexneri serotype 2a associated with sexual
- 460 transmission among gay, bisexual, and other men who have sex with men, in England: a descriptive
- 461 epidemiological study. Lancet Infect Dis. 2023 Jan 30.
- 462 25. Ogaz D, Allen H, Reid D, Brown JRG, Howarth AR, Pulford CV, et al. COVID-19 infection
- and vaccination uptake in men and gender-diverse people who have sex with men in the UK: analyses
- of a large, online community cross-sectional survey (RiiSH-COVID) undertaken November-
- 465 December 2021. BMC Public Health. 2023 May 5;23(1):829.
- 466 26. Curtis T, Bennett K, Mcdonagh L, Field N, Mercer C. P532 The sexual behaviour and health
- of heterosexual-identifying men who have sex with men: a systematic review. Sexually Transmitted
- 468 Infections. 2019;95(Suppl 1):A242-A.
- Desai S, Burns F, Schembri G, Williams D, Sullivan A, McOwan A, et al. Sexual behaviours
- and sexually transmitted infection outcomes in a cohort of HIV-negative men who have sex with men
- attending sexual health clinics in England. Int J STD AIDS. 2018 Dec;29(14):1407-16.
- 472 28. Mitchell HD, Desai S, Mohammed H, Ong KJ, Furegato M, Hall V, et al. Preparing for PrEP:
- estimating the size of the population eligible for HIV pre-exposure prophylaxis among men who have
- sex with men in England. Sex Transm Infect. 2019 Nov;95(7):484-7.
- 475 29. O'Halloran C, Owen G, Croxford S, Sims LB, Gill ON, Nutland W, et al. Current experiences
- of accessing and using HIV pre-exposure prophylaxis (PrEP) in the United Kingdom: a cross-
- 477 sectional online survey, May to July 2019. Euro Surveill. 2019 Nov;24(48):1900693.
- 478 30. Ogaz D, Logan L, Curtis TJ, McDonagh L, Guerra L, Bradshaw D, et al. PrEP use and unmet
- 479 PrEP-need among men who have sex with men in London prior to the implementation of a national
- PrEP programme, a cross-sectional study from June to August 2019. BMC Public Health. 2022 Jun
- 481 3;22(1):1105.
- 482 31. Wise J. Monkeypox: UK to run out of vaccine doses by next week. BMJ. 2022 Aug
- 483 18;378:o2053.
- 484 32. Heskin J, Dickinson M, Brown N, Girometti N, Feeney M, Hardie J, et al. Rapid
- 485 reconfiguration of sexual health services in response to UK autochthonous transmission of mpox
- 486 (monkeypox). Sex Transm Infect. 2023 Mar;99(2):81-4.
- 487 33. Jamard S, Handala L, Faussat C, Vincent N, Stefic K, Gaudy-Graffin C, et al. Resurgence of
- 488 symptomatic Mpox among vaccinated patients: First clues from a new-onset local cluster. Infect Dis
- 489 Now. 2023 Apr 28;53(4):104714.
- 490 34. Department of Health and Social Care. JCVI statement on vaccine dose prioritisation in
- response to the monkeypox outbreak. 2022 [cited 2023 01 April]; Available from:
- 492 https://www.gov.uk/government/publications/monkeypox-outbreak-jcvi-statement-on-vaccine-dose-

- 493 prioritisation-september-2022/jcvi-statement-on-vaccine-dose-prioritisation-in-response-to-the-
- 494 monkeypox-outbreak#updated-advice-september-2022
- 495 35. Paparini S, Whitacre R, Smuk M, Thornhill J, Mwendera C, Strachan S, et al. Public
- 496 understanding and awareness of and response to monkeypox virus outbreak: A cross-sectional survey
- of the most affected communities in the United Kingdom during the 2022 public health emergency.
- 498 HIV Med. 2022 Nov 16.

- 499 36. Dukers-Muijrers N, Evers Y, Widdershoven V, Davidovich U, Adam PCG, Op de Coul ELM,
- et al. Mpox vaccination willingness, determinants, and communication needs in gay, bisexual, and
- other men who have sex with men, in the context of limited vaccine availability in the Netherlands
- 502 (Dutch Mpox-survey). Front Public Health. 2022;10:1058807.
- 503 37. MacGibbon J, Cornelisse V, Smith AKJ, Broady TR, Hammoud MA, Bavinton BR, et al.
- Mpox (monkeypox) knowledge, concern, willingness to change behaviour, and seek vaccination:
- Results of a national cross-sectional survey. medRxiv. 2023:2022.12.01.22282999.
- Mercer CH, Prah P, Field N, Tanton C, Macdowall W, Clifton S, et al. The health and well-
- being of men who have sex with men (MSM) in Britain: Evidence from the third National Survey of
- Sexual Attitudes and Lifestyles (Natsal-3). BMC Public Health. 2016 Jul 7;16(1):525.
- 39. Queer Health. Everything we know about MPOX (Monkeypox) so far. 2023 [cited 2023 20]
- April]; Available from: https://www.queerhealth.info/projects/monkeypox
- 511 40. Logie CH. What can we learn from HIV, COVID-19 and mpox stigma to guide stigma-
- informed pandemic preparedness? J Int AIDS Soc. 2022 Dec;25(12):e26042.

	All RiiSH-Mpo participants	OX	Mpox diagnosis history*		No mpox diagrams history	nosis	
Total	% [column]	N	[column %]	n	[column %]	n	p- value
	100%	1,333	100%	35	100%	1,298	varue
Recruitment site							
Facebook	58%	769	80%	28	57%	741	
Grindr	24%	316	14%	5	24%	311	
Twitter	15%	198	6%	2	15%	196	
Instagram	1%	18	0%	0	1%	18	
Other	2%	32	0%	0	2%	32	0.099
Sociodemographic characteristics							
Median age (IQR, range)	45 (IQR: 35-55 16-78)	, range:	42 (IQR: 38-47, 1 25-58)	range:	45 (IQR: 35-55 16-78)	, range:	
Mean age (standard deviation)	44.8 (12.5)		42.2 (6.9)		44.8 (12.7)		
Age-group							
16-24	5%	63	0%	0	5%	63	
25-34	19%	256	9%	3	19%	253	
35-44	26%	343	51%	18	25%	325	
45-54	25%	327	34%	12	24%	315	
≥55	26%	344	6%	2	26%	342	<0.00
Age-group (binary)							
<35	24%	319	9%	3	24%	316	
≥35	76%	1,014	91%	32	76%	982	0.031
Gender identity and sex at birth							
Cisgender male	99%	1,314	100%	35	99%	1,279	
All other gender identity	1%	19	0%	0	1%	19	0.471
groups Sexual orientation							
Gay/homosexual	89%	1,187	91%	32	89%	1,155	
Bisexual†	11%	146	9%	3	11%	143	0.648
Ethnicity				+ +			
White	92%	1,223	86%	30	92%	1,193	+
All other ethnicities	8%	110	14%	5	8%	105	0.189
Country of birth				-	+		
UK	83%	1,113	63%	22	84%	1,091	+
Outside-UK	17%	220	37%	13	16%	207	0.001
Nation of residence							-
England	86%	1,148	97%	34	86%	1,114	1
Scotland, Wales, or N	14%	185	3%	1	14%	184	0.056
Ireland		1		-	1	1	2.000

D.1 1 1 1	270/	405	200/		200/	K11SH-M	pox v_1.
Below degree level	37%	495	20%	7	38%	488	0.022
Degree level or higher	63%	838	80%	28	62%	810	0.033
Employment	100/	250	00/		200/	256	
Not employed	19%	259	9%	3	20%	256	0.100
Current employment	81%	1,074	91%	32	80%	1,042	0.100
Household composition							
Lives with others	62%	827	63%	22	62%	805	
Lives alone	38%	506	37%	13	38%	493	0.920
Relationship status							
Single	44%	591	51%	18	44%	573	
In a relationship	56%	742	49%	17	56%	725	0.392
Comfortable financial situation							
No	52%	693	34%	12	52%	681	
Yes (top two quartiles)§	48%	640	66%	23	48%	617	0.034
Clinical and behavioural characteristics							
HIV status							
Negative/unknown	85%	1,131	63%	22	85%	1,109	
Living with HIV	15%	202	37%	13	15%	189	<0.00
HAV vaccination history (≥1 dose)							
No	32%	430	23%	8	33%	422	
Yes	68%	903	77%	27	67%	876	0.228
HBV vaccination history (≥1 dose)							
No	28%	379	14%	5	29%	374	
Yes	72%	954	86%	30	71%	924	0.060
HPV vaccination history (≥1 dose)							
No	58%	771	26%	9	59%	762	
Yes	42%	562	74%	26	41%	536	<0.00 1
SHS visit in last year							
No	36%	478	6%	2	37%	476	
Yes	64%	855	94%	33	63%	822	<0.00
STI tested in last year							
No	30%	405	3%	1	31%	404	
Yes	70%	928	97%	34	69%	894	<0.00
STI test positivity since August 2022							1
Never STI tested	9%	123	3%	1	9%	122	
Tested before August 2022	38%	513	20%	7	39%	506	
All negative/unknown recent test results since August 2022	41%	541	34%	12	41%	529	
≥1 recent positive test results since August 2022	12%	156	43%	15	11%	141	<0.00

						KIISH-IVI	pox v_1.
Recreational drug use							
associated with chemsex in							
last year‡ No	92%	1,222	77%	27	92%	1,195	
		, i					
Yes	8%	111	23%	8	8%	103	0.002
Number of recent male physical sex partners since August 2022							
None	8%	100	3%	1	8%	99	
1	14%	180	6%	2	14%	178	
2 to 4	29%	389	26%	9	29%	380	
5 to 9	21%	280	17%	6	21%	274	
≥10	29%	384	49%	17	28%	367	0.094
Met recent male physical sex partners in sex on premises venue, sex party, or PSE since August 2022							
No	67%	888	49%	17	67%	871	
Yes	33%	445	51%	18	33%	427	0.022
PrEP use since December 2021 (HIV negative/unknown status, n=1,131)¶							
No	47%	534	9%	2	48%	532	
Yes	53%	597	91%	20	52%	577	<0.00
Behaviour modification since May 2022 to avoid getting mpox**							
No	47%	626	51%	18	47%	608	
Yes	53%	707	49%	17	53%	690	0.592

*Participants with self-reported mpox test positivity. Those without mpox test positivity (i.e. no diagnosis history) include those without a known positive test (n=67) and those without a test history (n=1231). †Includes those identifying as bisexual, straight, or another way. §Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation". ‡Includes crystal methamphetamine, mephedrone or gammahydroxybutyrate/gamma-butyrolactone. ¶Excludes people living with HIV (n=202). **Behaviour modification includes self-report of any of the following from May 2022: fewer sexual partners, reduced visits to sex on premises venues or PSE (i.e. cruising grounds), and avoiding: all sex, condomless anal sex, skin-to-skin contact, or visiting clubs or crowds. HAV=Hepatitis A virus. HBV=Hepatitis B virus. HPV=Human papilloma virus. SHS=Sexual health service. STI=Sexually transmitted infection. PSE=Public sex environment (i.e. cruising grounds). PrEP=HIV pre-exposure prophylaxis. Percentages may not total 100 due to rounding.

514

Table 2. Behaviour modification measures and other precautions reported since May 2022 to avoid getting mpox by RiiSH-Mpox participants, November/December 2022

Behaviour modification measure(s) reported since May 2022*	n†	In all participants	In those reporting any
Senaviour mounteation measure(s) reported since ivaly 2022		(N=1,333)	modification measures (n=707)
Self-report of ≥1 behaviour modification measures since May 2022 to avoid getting mpox†	707	53%	100%
"I've chosen fewer sexual partners"	510	38%	72%
"I've reduced visits to or avoided sex-on-premises venues such as saunas and backrooms"	351	26%	50%
"I've avoided sex"	206	15%	29%
"I've reduced visits to or avoided cruising grounds"	185	14%	26%
"I've avoided nightclubs or other crowded spaces"	138	10%	20%
"I've avoided condomless sex"	106	8%	15%
"I've avoided skin-to-skin contact"	69	5%	10%
None of the above behaviour modification measures reported	626	47%	
Other precautions reported since May 2022*§	n†	In all participants (N=1,333)	
"I've asked potential sex partners if they've had a monkeypox vaccination"	187	14%	
"I've washed my hands more regularly"	129	10%	
"I've asked potential partners if they've had mpox symptoms"	124	9%	
"I've asked sexual partners for contact details for contact tracing"	22	2%	

^{*}Derived from the question: "Since the start of the UK monkeypox outbreak in May 2022, have you done any of the following in order to avoid getting monkeypox?" †Number of participants. Participants may have selected ≥1 behavioural modification measures listed (responses are not mutually exclusive). §Shown for information, not included as behavioural modification measures (responses are not mutually exclusive).

		Mpox vaccine offe	r and vaccination*		Mpox vaccination uptake	
	Total offered vaccine	a) Offered and vaccinated	b) Offered but not vaccinated	c) Not offered and not vaccinated	In those offered vaccine†	In all participants‡
Eligibility group	n (row %)	n (row %)	n (row %)	n (row %)	% (95% CI)	% (95% CI)
Eligible* for mpox vaccination (n=875)	655 (75%)	601 (69%)	54 (6%) §	220 (25%)**	92% (89%-94%)	69% (65%-72%)
Not eligible for mpox vaccination (n=458)	116 (25%)	91 (20%)	25 (5%)	342 (75%)	78% (70%-86%)	20% (16%-24%)
All RiiSH-Mpox participants (N=1,333)	771 (75%)	692 (52%)	79 (6%) ¶	562 (42%)††	90% (88%-92%)	52% (49%-55%)

^{*}Self-reporting any of the following: meeting recent male physical sex partners at sex on premises venues, sex parties, or PSE (i.e. cruising grounds) (since August 2022) OR \geq 10 recent male physical sex partners (since August 2022) OR recreational drug use associated with chemsex (in the last year) OR recent positive STI test (since August 2022) OR current PrEP use (since December 2021); †Percentage (%) reporting uptake of \geq 1 mpox vaccine dose(s) among those offered an mpox vaccine $[(a/(a+b)) \times 100\%]$. ‡Percentage (%) reporting uptake of \geq 1 mpox vaccine dose(s) among all group $[(a/(a+b+c)) \times 100\%]$. § Of participants mpox vaccine eligible and offered a vaccine, but not vaccinated (n=54): 28 (52%) were waiting to get vaccinated, 26 (48%) decided not to get vaccinated. ¶ Of all participants offered a mpox vaccine, but not vaccinated (n=79): 42 (53%) were waiting to get vaccinated, 37 (47%) decided not to get vaccinated. **Of those eligible and not offered, 38% (83/220) had visited an SHS since August 2022 and 57% (126/220) had visited an SHS in the last year. ††Of those not offered, 20% (111/562) had visited an SHS since August 2022 and 32% (182/562) had visited an SHS in the last year. 95% CI=95% confidence interval. SHS=Sexual health service. Percentages may not total 100 due to rounding.


	% RiiSH-Mpox participants		% Mpox vaccinated*	+ +										
Total	[column %]	n	[row %]	n	uOR	95	% C	Ī	p-value	aOR§§	9	95% C	I	p-value
	100%	1,333	52%	692										
Sociodemographic characteristics														
Median age (IQR, range)	45 (IQR: 35-55, range: 16-78)		45 (IQR: 36-54, range: 18-74)											
Mean age (standard deviation)	44.8 (12.5)		44.8 (11.7)											
Age-group†														
16-24	5%	63	30%	19	0.31	0.17	-	0.56		0.47	0.25	-	0.87	
25-34	19%	256	52%	133	0.78	0.56	-	1.08		0.79	0.56	-	1.11	
35-44	26%	343	55%	189	0.88	0.65	-	1.20		0.86	0.63	-	1.18	
45-54	25%	327	58%	190	1.00	(base)				1.00	(base)			
≥55	26%	344	47%	161	0.63	0.47	-	0.86	0.0002	0.79	0.57	-	1.09	0.1444
Gender identity and sex at birth														
Cisgender male	99%	1,314	52%	684	1.00	(base)				1.00	(base)			
All other gender identity groups	1%	19	42%	8	0.67	0.27	-	1.68	0.3885	1.05	0.40	-	2.79	0.922
Sexual orientation														
Gay/homosexual	89%	1,187	54%	645	1.00	(base)				1.00	(base)			
Bisexual‡	11%	146	32%	47	0.40	0.28	-	0.57	< 0.001	0.43	0.29	-	0.62	< 0.001
Ethnicity†														
White	92%	1,223	52%	635	1.00	(base)				1.00	(base)			
Other ethnicities	8%	110	52%	57	1.00	0.67	-	1.47	0.9834	1.06	0.70	-	1.61	0.7668
Country of birth														
UK	83%	1,113	51%	566	1.00	(base)				1.00	(base)			
Outside-UK	17%	220	57%	126	1.30	0.97	-	1.73	0.081	1.17	0.85	-	1.59	0.3374
Nation of residence														
England	86%	1,148	53%	613	1.00	(base)				1.00	(base)			

											1,	.1101	T TATE.	0.1 1_1.1
Scotland, Wales, or N Ireland	14%	185	43%	79	0.65	0.48	-	0.89	0.0069	0.64	0.46	-	0.89	0.0081
Educational qualifications														
Below degree-level	37%	495	40%	199	0.47	0.38	-	0.59		0.50	0.39	-	0.63	
Degree-level or higher	63%	838	59%	493	1.00	(base)			< 0.001	1.00	(base)	+		< 0.001
Employment								-				1	+	
Not employed	19%	259	37%	97	0.48	0.36	-	0.64		0.59	0.43	-	0.80	
Current employment	81%	1,074	55%	595	1.00	(base)	+		< 0.001	1.00	(base)	+	_	0.0007
Household composition												+		
Lives with others	62%	827	50%	414	0.82	0.66	-	1.03		0.81	0.65	-	1.03	
Lives alone	38%	506	55%	278	1.00	(base)		-+	0.0834	1.00	(base)	+	+	0.084
Relationship status		+									-	+	+	
Single	44%	591	54%	320	1.17	0.95	-	1.46		1.27	1.01	+-	1.60	
In a relationship	56%	742	50%	372	1.00	(base)	+ +		0.1453	1.00	(base)	+	+	0.0433
Comfortable financial situation												+	+	-
No	52%	693	48%	331	0.71	0.57	1-	0.88		0.90	0.71	-	1.14	
Yes (top two quartiles)§	48%	640	56%	361	1.00	(base)			0.0016	1.00	(base)	+	+	0.3774
Clinical and behavioural characteristics												+		
HIV status												+	<u> </u>	
Negative/unknown	85%	1,131	51%	575	1.00	(base)				1.00	(base)	+		
Living with HIV	15%	202	58%	117	1.33	0.98	-	1.80	0.0629	1.37	1.00	-	1.89	0.0517
HAV, HBV, or HPV vaccination history¶												+		
No	18%	246	20%	48	1.00	(base)	+ +			1.00	(base)	+		
Yes	82%	1,087	59%	644	6.00	4.28	-	8.41	< 0.001	5.27	3.72	-	7.47	<0.001
Behaviour modification since May 2022 to avoid getting mpo	x#											+		
No	47%	626	39%	247	1.00	(base)	++	+		1.00	(base)	+	<u> </u>	
Yes	53%	707	63%	445	1.77	1.42	-	2.20	< 0.001	1.63	1.30	-	2.04	<0.001
Mpox vaccination proxy eligibility criteria							$\dagger \dagger$	+				+	<u> </u>	
STI test positive since August 2022							++	$\overline{}$				+	<u> </u>	
No	88%	1,177	48%	568	1.00	(base)	+	\longrightarrow		1.00	(base)	—	+	+

										-	1110	1111	
12%	156	79%	124	4.15	2.77	-	6.23	< 0.001	4.09	2.69	-	6.22	
55%	734	31%	228	1.00	(base)				1.00	(base)			
45%	599	77%	464	7.63	5.96	-	9.77	< 0.001	7.09	5.49	-	9.15	<0.001
92%	1,222	50%	617	1.00	(base)				1.00	(base)			+
8%	111	68%	75	2.04	1.35	-	3.09	0.0005	2.03	1.32	-	3.12	0.001
													+
8%	100	31%	31	1.52	0.88	-	2.64		1.55	0.88	-	2.73	+
14%	180	23%	41	1.00	(base)				1.00	(base)			+
29%	389	44%	170	2.63	1.76	-	3.93		2.65	1.75	-	4.00	
21%	280	64%	180	6.10	3.99	-	9.34		6.36	4.10	-	9.87	+
29%	384	70%	270	8.03	5.32	-	12.1	< 0.001	7.73	5.06	-	11.8	< 0.001
													+
71%	949	44%	422	1.00	(base)				1.00	(base)			+
29%	384	70%	270	2.96	2.30	-	3.81	< 0.001	2.78	2.14	-	3.62	< 0.001
67%	888	43%	382	1.00	(base)				1.00	(base)			
33%	445	70%	310	3.04	2.39	-	3.87	< 0.001	2.80	2.18	-	3.60	< 0.001
					1								
34%	458	20%	91	1.00	(base)				1.00	(base)			+
66%	875	69%	601	8.85	6.75	-	11.6	< 0.001	8.38	6.35	-	11.1	< 0.001
0070	""		001										
	55% 45% 92% 8% 8% 14% 29% 21% 29% 71% 29% 67% 33%	55% 734 45% 599 92% 1,222 8% 111 8% 100 14% 180 29% 389 21% 280 29% 384 71% 949 29% 384 67% 888 33% 445 34% 458	55% 734 31% 45% 599 77% 92% 1,222 50% 8% 111 68% 8% 100 31% 14% 180 23% 29% 389 44% 29% 384 70% 71% 949 44% 29% 384 70% 67% 888 43% 33% 445 70% 34% 458 20%	55% 734 31% 228 45% 599 77% 464 92% 1,222 50% 617 8% 111 68% 75 8% 100 31% 31 14% 180 23% 41 29% 389 44% 170 21% 280 64% 180 29% 384 70% 270 71% 949 44% 422 29% 384 70% 270 67% 888 43% 382 33% 445 70% 310 34% 458 20% 91	55% 734 31% 228 1.00 45% 599 77% 464 7.63 92% 1,222 50% 617 1.00 8% 111 68% 75 2.04 8% 100 31% 31 1.52 14% 180 23% 41 1.00 29% 389 44% 170 2.63 21% 280 64% 180 6.10 29% 384 70% 270 8.03 71% 949 44% 422 1.00 29% 384 70% 270 2.96 67% 888 43% 382 1.00 33% 445 70% 310 3.04 34% 458 20% 91 1.00	55% 734 31% 228 1.00 (base) 45% 599 77% 464 7.63 5.96 92% 1,222 50% 617 1.00 (base) 8% 111 68% 75 2.04 1.35 8% 100 31% 31 1.52 0.88 14% 180 23% 41 1.00 (base) 29% 389 44% 170 2.63 1.76 21% 280 64% 180 6.10 3.99 29% 384 70% 270 8.03 5.32 71% 949 44% 422 1.00 (base) 29% 384 70% 270 2.96 2.30 67% 888 43% 382 1.00 (base) 33% 445 70% 310 3.04 2.39 34% 458 20% 91 1.00 (base)	55% 734 31% 228 1.00 (base) 45% 599 77% 464 7.63 5.96 - 92% 1,222 50% 617 1.00 (base) 8% 111 68% 75 2.04 1.35 - 8% 100 31% 31 1.52 0.88 - 14% 180 23% 41 1.00 (base) 29% 389 44% 170 2.63 1.76 - 29% 384 70% 270 8.03 5.32 - 71% 949 44% 422 1.00 (base) 29% 384 70% 270 2.96 2.30 - 67% 888 43% 382 1.00 (base) 33% 445 70% 310 3.04 2.39 - 34% 458 20% 91 1.00 (base)	55% 734 31% 228 1.00 (base) - 45% 599 77% 464 7.63 5.96 - 9.77 92% 1,222 50% 617 1.00 (base) - - 3.09 8% 111 68% 75 2.04 1.35 - 3.09 8% 100 31% 31 1.52 0.88 - 2.64 14% 180 23% 41 1.00 (base) - 2.64 29% 389 44% 170 2.63 1.76 - 3.93 21% 280 64% 180 6.10 3.99 - 9.34 29% 384 70% 270 8.03 5.32 - 12.1 71% 949 44% 422 1.00 (base) - 29% 384 70% 270 2.96 2.30 - 3.81 67% 888 43% 382 1.00 (base) - 3.87 </td <td>55% 734 31% 228 1.00 (base) - 45% 599 77% 464 7.63 5.96 - 9.77 <0.001</td> 92% 1,222 50% 617 1.00 (base) - - 3.09 0.0005 8% 111 68% 75 2.04 1.35 - 3.09 0.0005 8% 100 31% 31 1.52 0.88 - 2.64 14% 180 23% 41 1.00 (base) - 2.64 29% 389 44% 170 2.63 1.76 - 3.93 21% 280 64% 180 6.10 3.99 - 9.34 29% 384 70% 270 8.03 5.32 - 12.1 <0.001	55% 734 31% 228 1.00 (base) - 45% 599 77% 464 7.63 5.96 - 9.77 <0.001	55% 734 31% 228 1.00 (base)	12%	12%	1.00 1.00


^{*}Participants with self-reported uptake of ≥1 mpox vaccine dose(s).†Selected *a priori* for model inclusion. ‡Includes those identifying as bisexual, straight, or another way. \$Top two quartiles ("I am comfortable" from the question, "How would you best describe your current financial situation". ¶Participants self-reporting uptake of ≥1 HAV, HBV, or HPV vaccine dose(s). **Behaviour modification includes self-report of any of the following from May 2022: fewer sexual partners, reduced visits to sex on premises venues or PSE (i.e. cruising grounds), and avoiding: all sex, condomless anal sex, skin-to-skin contact, or visiting clubs or crowds. #Includes people living with HIV (n=202); those reporting a new HIV diagnosis in the last 5 years were included in questions addressing PrEP use. Among those with a HIV negative/unknown status (n=1,131), 78% of PrEP users since December 2021 (vs 21% of non-users) reported mpox vaccination (aOR: 12.2 [95% CI: 9.07-16.3]). ††Includes crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone.§\$Self-report of any mpox vaccination proxy eligibility criteria. ‡‡Adjusted for age-group, ethnicity, sexual orientation, educational qualifications, employment, and financial situation. HAV=Hepatitis A virus. HBV=Hepatitis B virus. HPV=Human papilloma virus. SHC=Sexual health clinic. STI=Sexually transmitted infection. PSE=Public sex environment (i.e. cruising grounds). PrEP=HIV pre-exposure prophylaxis. PLWHIV=People living with HIV. uOR=Unadjusted odds ratio. aOR=adjusted odds ratio. Percentages may not total 100 due to rounding.

Appendix I: RiiSH-Mpox participant flowchart




Appendix II: Self-reported mpox positivity and self-perceived mpox in RiiSH-Mpox participants, November/December 2022

522




Appendix III. Mpox vaccination and offered reported in all RiiSH-Mpox participants and those considered mpox vaccine eligible, November/December 2022

a) all participants



*Question preamble: "Vaccination for monkeypox involves having two doses of vaccine." †Vaccine offer assumed in those reporting ≥1 vaccine dose(s). §Question: "Have you been offered a second vaccine for monkeypox?" ¶Question: "If offered, to what extent would you be willing to be vaccinated against monkeypox?"

b) all participants considered mpox vaccine eligible



*Self-reporting any of the following: meeting recent male physical sex partners at sex on premises venues, sex parties, or PSE (i.e. cruising grounds) (since August 2022) OR ≥10 recent male physical sex partners (since August 2022) OR recreational drug use associated with chemsex (in the last year) OR recent positive STI test (since August 2022) OR current PrEP use (on/after December 2021); excludes those that were vaccinated but not considered eligible (n=91, 13.2% of all vaccinated) and those not vaccinated or considered eligible for mpox vaccination (n=367) †Preamble: "Vaccination for monkeypox involves having two doses of vaccine." ‡Vaccine offer assumed in those reporting ≥1 vaccine dose(s). § Question: "Have you been offered a second vaccine for monkeypox?" ¶Question: "If offered, to what extent would you be willing to be vaccinated against monkeypox?".

	All RiiSH-Mpc participants	DX	Mpox diagnosis history or self- perceived mpox		No mpox diagonistory or self- perceived mpo	-	
Total	% [column]	N	% [column]	n	% [column]	n	p- value
	100%	1333	100%	52	100%	1281	
Recruitment site							
Facebook	58%	769	75%	39	57%	730	
Grindr	24%	316	15%	8	24%	308	
Twitter	15%	198	8%	4	15%	194	
Instagram	1%	18	0%	0	1%	18	
Other	2%	32	2%	1	2%	31	0.134
Sociodemographic characteristics							
Median age (IQR, range)	45 (IQR: 35-55 16-78)	, range:	42 (IQR: 38-47, 24-68)	range:	45 (IQR: 35-55 16-78)	, range:	
Mean age (standard deviation)	44.8 (12.5)	_	42.6 (8.5)		44.8 (12.7)		
Age-group							
16-24	5%	63	2%	1	5%	62	
25-34	19%	256	10%	5	20%	251	
35-44	26%	343	48%	25	25%	318	
45-54	25%	327	31%	16	24%	311	
≥55	26%	344	10%	5	26%	339	<0.00
Age-group (binary)							
<35	24%	319	12%	6	24%	313	
≥35	76%	1014	88%	46	76%	968	0.033
Gender identity and sex at birth							
Cisgender male	99%	1314	100%	52	99%	1,262	
All other gender identity groups	1%	19	0%	0	1%	19	0.376
Sexual orientation							
Gay/homosexual	89%	1187	94%	49	89%	1,138	
Bisexual†	11%	146	6%	3	11%	143	0.222
Ethnicity		1					
White	92%	1223	87%	45	92%	1,178	
All other ethnicities	8%	110	13%	7	8%	103	0.164
Country of birth		1					
UK	83%	1113	67%	35	84%	1,078	
Outside-UK	17%	220	33%	17	16%	203	0.001
Nation of residence						+ +	
England	86%	1148	94%	49	86%	1,099	

						RiiSH-M	pox v_1.
Scotland, Wales, or N Ireland	14%	185	6%	3	14%	182	0.084
Educational qualifications							
Below degree level	37%	495	19%	10	38%	485	
Degree level or higher	63%	838	81%	42	62%	796	0.006
Employment							
Not employed	19%	259	13%	7	20%	252	
Current employment	81%	1074	87%	45	80%	1,029	0.267
Household composition							
Lives with others	62%	827	65%	34	62%	793	
Lives alone	38%	506	35%	18	38%	488	0.612
Relationship status							
Single	44%	591	46%	24	44%	567	
In a relationship	56%	742	54%	28	56%	714	0.788
Comfortable financial							
situation							
No	52%	693	40%	21	52%	672	
Yes (top two quartiles)	48%	640	60%	31	48%	609	0.088
Clinical and behavioural characteristics							
HIV status							
Negative/unknown	85%	1131	69%	36	85%	1095	
Living with HIV	15%	202	31%	16	15%	186	0.001
HAV vaccination history							
(≥1 dose)							
No	32%	430	29%	15	32%	415	
Yes	68%	903	71%	37	68%	866	0.591
HBV vaccination history (≥1 dose)							
No	28%	379	21%	11	29%	368	
Yes	72%	954	79%	41	71%	913	0.235
HPV vaccination history							
(≥1 dose)							
No	58%	771	33%	17	59%	754	
Yes	42%	562	67%	35	41%	527	<0.00 1
SHS visit in last year							1
No	36%	478	12%	6	37%	472	
Yes	64%	855	88%	46	63%	809	<0.00
STI tested in last year							1
No	30%	405	10%	5	31%	400	
Yes	70%	928	90%	47	69%	881	0.001
STI test positivity since August 2022							
Never STI tested	9%	123	2%	1	10%	122	
Tested before August 2022	38%	513	27%	14	39%	499	
All negative/unknown recent test results since August 2022	41%	541	37%	19	41%	522	

RiiSH	-Mpox	V	1.0	١

							.pox v_1.0
≥1 recent positive test results since August 2022	12%	156	35%	18	11%	138	<0.00
Recreational drug use associated with chemsex in							
last year§	020/	1222	700/	41	020/	1101	
No	92%	1222	79%	41	92%	1181	
Yes	8%	111	21%	11	8%	100	0.001
Number of recent male physical sex partners since August 2022							
None	8%	100	2%	1	8%	99	
1	14%	180	6%	3	14%	177	
2 to 4	29%	389	23%	12	29%	377	
5 to 9	21%	280	21%	11	21%	269	
≥10	29%	384	48%	25	28%	359	0.015
Met recent male physical sex partners in sex on premises venue, sex party, or PSE since Aug 2022							
No	67%	888	46%	24	67%	864	
Yes	33%	445	54%	28	33%	417	0.001
PrEP use since December 2021 (HIV negative/unknown status, n=1131);							
No	47%	534	17%	6	48%	528	
Yes	53%	597	83%	30	52%	567	<0.00
Behaviour modification since May 2022 to avoid getting mpox¶							
No	47%	626	50%	26	47%	600	
Yes	53%	707	50%	26	53%	681	0.654

^{*}Participants with self-reported mpox test positivity. Those without mpox test positivity (i.e. no diagnosis history) include those without a known positive test (n=67) and those without a test history (n=1231). †Includes those identifying as bisexual, straight, or another way. ‡Excludes people living with HIV (n=202). § Includes crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone. ¶Behaviour modification includes self-report of any of the following from May 2022: fewer sexual partners, reduced visits to sex on premises venues or PSE (i.e. cruising grounds), and avoiding: all sex, condomless anal sex, skin-to-skin contact, or visiting clubs or crowds. HAV=Hepatitis A virus. HBV=Hepatitis B virus. HPV=Human papilloma virus. SHS=Sexual health service. STI=Sexually transmitted infection. PSE=Public sex environment (i.e. cruising grounds). PrEP=HIV pre-exposure prophylaxis. Percentages may not total 100 due to rounding.

						1						-		
	% RiiSH-Mpox participants assumed vaccine eligible*		% Mpox vaccinated†											
Total	[column %]	n	[row %]	n	uOR	95	% C	CI	p-value	aOR**	95	% (CI	p-value
	100%	875	69%	601										
Sociodemographic characteristics														
Median age (IQR, range)	45 (IQR: 36-54; range: 17-78)		45 (IQR: 36-53; range: 18-74)											
Mean age (standard deviation)	44.9 (12.0)		44.7 (11.7)											
Age-group‡														
16-24	3%	29	55%	16	0.44	0.20	-	0.97		0.57	0.25	-	1.33	
25-34	19%	164	71%	117	0.89	0.56	-	1.39		0.88	0.55	-	1.40	
35-44	28%	243	68%	166	0.77	0.51	-	1.15		0.72	0.48	-	1.09	
45-54	25%	221	74%	163	1.00	(base)				1.00	(base)			
≥55	25%	218	64%	139	0.63	0.42	-	0.94	0.0915	0.76	0.50	-	1.18	0.4711
Gender identity and sex at birth														
Cisgender male	99%	862	69%	594	1.00	(base)				1.00	(base)			
All other gender groups	1%	13	54%	7	0.53	0.18	-	1.58	0.2603	0.75	0.24	-	2.38	
Sexual orientation														
Gay/homosexual	91%	795	70%	559	1.00	(base)				1.00	(base)			
Bisexual§	9%	80	53%	42	0.47	0.29	-	0.74	0.0015	0.49	0.30	-	0.79	0.0037
Ethnicity‡														
White	92%	802	69%	552	1.00	(base)				1.00	(base)			
Other ethnicities	8%	73	67%	49	0.92	0.55	-	1.54	0.7646	1.01	0.59	-	1.73	0.9749

												1/11	D11-141	POX_{-1}
Country of birth														
UK	82%	721	68%	492	1.00	(base)				1.00	(base)			
Outside-UK	18%	154	71%	109	1.13	0.77	-	1.65	0.081	1.03	0.68	-	1.54	0.8998
Nation of residence														
England	87%	760	69%	528	1.00	(base)				1.00	(base)			
Scotland, Wales, or N Ireland	13%	115	63%	73	0.76	0.51	-	1.15	0.2015	0.75	0.49	-	1.14	0.1821
Educational qualifications														
Below degree-level	33%	291	57%	165	0.44	0.33	-	0.60		0.46	0.34	-	0.63	
Degree-level or higher	67%	584	75%	436	1.00	(base)			<0.001	1.00	(base)			<0.001
Employment														
Not employed	16%	144	56%	80	0.50	0.35	-	0.73		0.63	0.42	-	0.95	
Current employment	84%	731	71%	521	1.00	(base)			0.0003	1.00	(base)			0.0286
Household composition														
Lives with others	60%	527	68%	358	0.92	0.68	-	1.23		0.91	0.67	-	1.24	
Lives alone	40%	348	70%	243	1.00	(base)			0.5535	1.00	(base)			0.5565
Relationship status														
Single	45%	397	71%	281	1.20	0.90	-	1.60		1.24	0.92	-	1.68	
In a relationship	55%	478	67%	320	1.00	(base)			0.2227	1.00	(base)			0.1571
Comfortable financial situation														
No	48%	420	66%	278	0.80	0.60	1	1.07		1.00	0.74	-	1.35	
Yes (top two quartiles)	52%	455	71%	323	1.00	(base)			0.1263	1.00	(base)			0.9896
Clinical and behavioural characteristics														
HIV status														
Negative/unknown	87%	759	69%	523	1.00	(base)				1.00	(base)			
Living with HIV	13%	116	67%	78	0.93	0.61	-	1.41	0.7197	1.02	0.66	-	1.58	0.9269

HAV, HBV, or HPV vaccination history¶														_
No	10%	91	35%	32	1.00	(base)				1.00	(base)			
Yes	90%	784	73%	569	4.88	3.09	-	7.71	< 0.001	4.42	2.74	-	7.13	< 0.001
Behaviour modification since May 2022 to avoid getting mpox#														
No	45%	398	62%	246	1.00	(base)				1.00	(base)			
Yes	55%	477	74%	355	1.80	1.35	-	2.40	0.0001	1.63	1.21	-	2.20	0.0013

^{*}Mpox vaccine eligibility was defined as the report of any of the following since August 2022: ≥10 physical male sex partners; meeting any physical male sex partners in a sex on premises venue, sex party, or PSE (i.e. cruising grounds); a positive STI test; or in the last year, report of: PrEP use (as a proxy for those at risk of mpox acquisition); or use of recreational drugs associated with chemsex (crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone). †Participants with self-reported uptake of ≥1 mpox vaccine dose(s).‡Selected *a priori* for model inclusion. §Includes those identifying as bisexual, straight, or another way. ¶Participants self-reporting uptake of ≥1 HAV, HBV, or HPV vaccine dose(s). #Behaviour modification includes self-report of any of the following from May 2022: fewer sexual partners, reduced visits to sex on premises venues or PSE (i.e. cruising grounds), and avoiding: all sex, condomless anal sex, skin-to-skin contact, or visiting clubs or crowds. **Adjusted for age-group, ethnicity, sexual orientation, educational qualifications, employment. HAV=Hepatitis A virus. HBV=Hepatitis B virus. HPV=Human papilloma virus. SHS=Sexual health service. uOR=Unadjusted odds ratio. aOR=adjusted odds ratio. Percentages may not total 100 due to rounding.

Appendix VI. Mpox vaccine offer and uptake among RiiSH-Mpox participants considered eligible for mpox vaccination (sensitivity analysis, ≥5 recent male physical sex partners), November/December 2022

		Mpox vaccine offer	and vaccination		Mpox vaccination uptake		
	Total offered vaccine	a) Offered and vaccinated	b) Offered but not vaccinated	c) Not offered and not vaccinated	In those offered vaccine†	In all participants:	
Eligibility group	n (row %)	n (row %)	n (row %)	n (row %)	% (95% CI)	% (95% CI)	
Eligible* for mpox vaccination (n=951) (sensitivity analysis)	685 (72%)	626 (66%)	59 (6%)	266 (28%)	91% (89%-93%)	66% (63%-69%)	
All RiiSH-Mpox participants (N=1,333)	771 (75%)	692 (52%)	79 (6%)	562 (42%)	90% (88%-92%)	52% (49%-55%)	

^{*}Self-reporting any of the following: meeting recent male physical sex partners at sex on premises venues, sex parties, or PSE (i.e. cruising grounds) (since August 2022) OR \geq 5 recent male physical sex partners (since August 2022) OR recreational drug use associated with chemsex (in the last year) OR recent positive STI test (since August 2022) OR current PrEP use (since December 2021); †Percentage (%) reporting uptake of \geq 1 mpox vaccine dose(s) among those offered an mpox vaccine [(a/(a+b))*100%]. ‡Percentage (%) reporting uptake of \geq 1 mpox vaccine dose(s) among all group [(a/(a+b+c))*100%].